Advertisement

Palliative Care Emergencies

  • G. Zeppetella
Chapter

Abstract

Patients receiving palliative care may deteriorate suddenly due to their illness or another acute medical or surgical problem. Management options depend on life expectancy, level of intervention needed, and an assessment of risks, benefits, side effects, and likely outcome.

Keywords

Palliative Care Zoledronic Acid Tranexamic Acid Pharmacological Management Ibandronic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Falk S, Reid C. Emergencies. In: Fallon M, Hanks G, editors. ABC of palliative care. 2nd ed. Oxford: Blackwell Publishing; 2006. p. 40–3.Google Scholar
  2. 2.
    Harris DG, Noble SI. Management of terminal hemorrhage in patients with advanced cancer: a systematic literature review. J Pain Symptom Manage. 2009;38:913–27.PubMedCrossRefGoogle Scholar
  3. 3.
    British National Formulary. BNF 61. London: BMJ Group and Pharmaceutical Press; 2011. Available at: www.bnf.org. Last accessed 27 Nov 2011.
  4. 4.
    Palliative Drugs. Essential independent drug information for palliative and hospice care. Formulary 2011. Available at: www.palliativedrugs.com. Last accessed 27 Nov 2011.
  5. 5.
    Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist. 2004;9:561–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Green D, Thompson JA, Montgomery B. Oncologic emergencies. In: Irwin RS, Rippe JM, editors. Intensive care medicine. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1419–30.Google Scholar
  7. 7.
    Bower M, Cox S. Endocrine and metabolic complications of advanced cancer. In: Hanks G, Cherny N, Kaasa S, et al., editors. Oxford textbook of palliative medicine. 4th ed. Oxford: Oxford University Press; 2010. p. 1015–33.Google Scholar
  8. 8.
    Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer. 2005;12:549–83.PubMedCrossRefGoogle Scholar
  9. 9.
    Ralston SH, Coleman R, Fraser WD, et al. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990;112:499–504.PubMedGoogle Scholar
  10. 10.
    Hemphill RR. Hypercalcemia. Available at: www.emedicine.medscape.com/article/240681-overview. Last accessed 27 Nov 2011.
  11. 11.
    Waters M. Hypercalcaemia. InnovAiT. 2009;2:698–701.CrossRefGoogle Scholar
  12. 12.
    Loblaw DA, Perry J, Chambers A, et al. A population-based study of malignant spinal cord compression in Ontario. Clin Oncol. 2003;15:211–7.CrossRefGoogle Scholar
  13. 13.
    Bach F, Larsen BH, Rohde K, et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations, and prognosis in 398 patients with spinal cord compression. Acta Neurochir. 1990;107:37–43.CrossRefGoogle Scholar
  14. 14.
    Conway R, Graham J, Kidd J, Levack P. What happens to people after malignant cord compression? Survival, function, quality of life, emotional well-being and place of care 1 month after diagnosis. Clin Oncol. 2007;19:56–62.CrossRefGoogle Scholar
  15. 15.
    Akram H, Allibone J. Spinal surgery for palliation in malignant spinal cord compression. Clin Oncol. 2010;22:792–800.CrossRefGoogle Scholar
  16. 16.
    National Institute for Health and Clinical Excellence. Metastatic spinal cord compression. NICE clinical guidelines 75. London: National Collaborating Centre for Cancer; 2008.Google Scholar
  17. 17.
    George R, Jeba J, Ramkumar G, et al. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev. 2008;(4):CD006716.Google Scholar
  18. 18.
    Eleraky M, Papanastassiou I, Vrionis FD. Management of metastatic spine disease. Curr Opin Support Palliat Care. 2010;4:182–8.PubMedCrossRefGoogle Scholar
  19. 19.
    National Institute for Health and Clinical Excellence. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients. Scope. Available at: www.nice.org.uk/nicemedia/live/12349/49068/49068.pdf. Last accessed 27 Nov 2011.
  20. 20.
    Oppenheim BA, Anderson H. Management of febrile neutropenia in low risk cancer patients. Thorax. 2000;55 suppl 1:S63–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Rossetti AO, Stupp R. Epilepsy in brain tumor patients. Curr Opin Neurol. 2010;23:603–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Palliative Care Guidelines. Emergencies in palliative care. Available at: www.palliativecareguidelines.scot.nhs.uk/documents/Seizures.pdf. Last accessed 27 Nov 2011.
  23. 23.
    Fraser Health. Hospice palliative care program symptom guidelines: twitching/myoclonus/ seizures. 2006. Available at: www.fraserhealth.ca/media/19FHSymptomGuidelinesMyoclonus.pdf. Last accessed 27 Nov 2011.
  24. 24.
    Ostler PJ, Clarke DP, Watkinson AF, Gaze MN. Superior vena cava obstruction: a modern management strategy. Clin Oncol. 1997;9:83–9.CrossRefGoogle Scholar
  25. 25.
    Falk S, Fallon M. ABC of palliative care: emergencies. 1997. Available at: www.bmj.com/content/315/7121/1525.full. Last accessed 27 Nov 2011.
  26. 26.
    Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev. 2001;(4):CD001316.Google Scholar

Copyright information

© Springer-Verlag London 2012

Authors and Affiliations

  • G. Zeppetella
    • 1
  1. 1.St Clare HospiceHastingwoodUK

Personalised recommendations